• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form FWP filed by AbbVie Inc.

    2/18/25 9:25:54 PM ET
    $ABBV
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ABBV alert in real time by email
    FWP 1 tm255723d5_fwp.htm FWP

    Filed pursuant to Rule 433
    Dated February 18, 2025
    Issuer Free Writing Prospectus supplementing the
    Preliminary Prospectus Supplement dated
    February 18, 2025 and the
    Prospectus dated February 14, 2025
    Registration No. 333-284980

     

    AbbVie Inc.

     

    Pricing Term Sheet

     

    $1,250,000,000 4.650% Senior Notes due 2028 (the “2028 Notes”)

    $1,000,000,000 4.875% Senior Notes due 2030 (the “2030 Notes”)

    $1,000,000,000 5.200% Senior Notes due 2035 (the “2035 Notes”)

    $750,000,000 5.600% Senior Notes due 2055 (the “2055 Notes”)

     

    Terms Applicable to Each Series of the Notes

     

    Issuer: AbbVie Inc.
       
    Trade Date: February 18, 2025
       
    Settlement Date*: February 26, 2025 (T+6)
       
    Ratings**: A3 (Positive) by Moody’s Investors Service, Inc. / A- (Stable) by Standard & Poor’s Ratings Group Inc.
       
    Form of Offering: SEC Registered (Registration No. 333-284980)
       
    Joint Book-Running Managers: BofA Securities, Inc. (All Notes)
      J.P. Morgan Securities LLC (All Notes)
      Morgan Stanley & Co. LLC (All Notes)
      Barclays Capital Inc. (All Notes)
      Mizuho Securities USA LLC (All Notes)
      BNP Paribas Securities Corp. (2028 Notes)
      Citigroup Global Markets Inc. (2055 Notes)
      Deutsche Bank Securities Inc. (2030 Notes)
      Goldman Sachs & Co. LLC (2055 Notes)
      HSBC Securities (USA) Inc. (2030 Notes)
      SG Americas Securities, LLC (2035 Notes)
      Wells Fargo Securities, LLC (2035 Notes)
       
    Co-Managers: BNP Paribas Securities Corp. (2030 Notes, 2035 Notes, 2055 Notes)
      Citigroup Global Markets Inc. (2028 Notes, 2030 Notes, 2035 Notes)
      Deutsche Bank Securities Inc. (2028 Notes, 2035 Notes, 2055 Notes)
      Goldman Sachs & Co. LLC (2028 Notes, 2030 Notes, 2035 Notes)
      HSBC Securities (USA) Inc. (2028 Notes, 2035 Notes, 2055 Notes)
      SG Americas Securities, LLC (2028 Notes, 2030 Notes, 2055 Notes)
      Wells Fargo Securities, LLC (2028 Notes, 2030 Notes, 2055 Notes)
      Lloyds Securities Inc. (All Notes)
      MUFG Securities Americas Inc. (All Notes)
      Santander US Capital Markets LLC (All Notes)
      TD Securities (USA) LLC (All Notes)
      U.S. Bancorp Investments, Inc. (All Notes)
      Siebert Williams Shank & Co., LLC (All Notes)
      Bancroft Capital, LLC (All Notes)
      Cabrera Capital Markets LLC (All Notes)
      Independence Point Securities LLC (All Notes)
      R. Seelaus & Co., LLC (All Notes)
       
    Interest Payment Dates: March 15 and September 15, commencing September 15, 2025
       
    Day Count Convention: 30 / 360

     

     

     

     

     

     

    Terms Applicable to 4.650% Senior Notes due 2028

     

    Aggregate Principal Amount: $1,250,000,000
    Final Maturity Date: March 15, 2028
    Public Offering Price: 99.867%, plus accrued and unpaid interest, if any, from February 26, 2025
    Benchmark Treasury: 4.250% due February 15, 2028
    Benchmark Treasury Price and Yield: 99-25 ¼ / 4.326%
    Spread to Benchmark Treasury: T+37 bps
    Coupon: 4.650%
    Yield to Maturity: 4.696%
    Make-Whole Call: Make-whole call at T+10 bps
    Par Call: On or after February 15, 2028
    CUSIP / ISIN: 00287Y DY2 / US00287YDY23

     

     

     

    Terms Applicable to 4.875% Senior Notes due 2030

     

    Aggregate Principal Amount: $1,000,000,000
    Final Maturity Date: March 15, 2030
    Public Offering Price: 99.908%, plus accrued and unpaid interest, if any, from February 26, 2025
    Benchmark Treasury: 4.250% due January 31, 2030
    Benchmark Treasury Price and Yield: 99-11+ / 4.395%
    Spread to Benchmark Treasury: T+50 bps
    Coupon: 4.875%
    Yield to Maturity: 4.895%
    Make-Whole Call: Make-whole call at T+10 bps
    Par Call: On or after February 15, 2030
    CUSIP / ISIN: 00287Y DZ9 / US00287YDZ97

     

     

     

    Terms Applicable to 5.200% Senior Notes due 2035

     

    Aggregate Principal Amount: $1,000,000,000
    Final Maturity Date: March 15, 2035
    Public Offering Price: 99.857%, plus accrued and unpaid interest, if any, from February 26, 2025
    Benchmark Treasury: 4.625% due February 15, 2035
    Benchmark Treasury Price and Yield: 100-19+ / 4.548%
    Spread to Benchmark Treasury: T+67 bps
    Coupon: 5.200%
    Yield to Maturity: 5.218%
    Make-Whole Call: Make-whole call at T+15 bps
    Par Call: On or after December 15, 2034
    CUSIP / ISIN: 00287Y EA3 / US00287YEA38

     

     

     

    Terms Applicable to 5.600% Senior Notes due 2055

     

    Aggregate Principal Amount: $750,000,000
    Final Maturity Date: March 15, 2055
    Public Offering Price: 99.750%, plus accrued and unpaid interest, if any, from February 26, 2025
    Benchmark Treasury: 4.500% due November 15, 2054
    Benchmark Treasury Price and Yield: 95-15 / 4.787%
    Spread to Benchmark Treasury: T+83 bps
    Coupon: 5.600%
    Yield to Maturity: 5.617%
    Make-Whole Call: Make-whole call at T+15 bps
    Par Call: On or after September 15, 2054
    CUSIP / ISIN: 00287Y EB1 / US00287YEB11

     

     

     

     2 

     

     

    The Issuer has filed a registration statement (including a preliminary prospectus supplement and an accompanying prospectus) with the Securities and Exchange Commission (“SEC”) for the offering to which this communication relates.  Before you invest, you should read the prospectus in that registration statement and other documents that the Issuer has filed with the SEC, including the preliminary prospectus supplement, for more complete information about the Issuer and this offering.  You may get these documents for free by visiting the SEC website at www.sec.gov.  Alternatively, the Issuer, any underwriter or any dealer participating in the offering will arrange to send you the preliminary prospectus supplement and the accompanying prospectus if you request it by contacting BofA Securities, Inc. at 1-800-294-1322, J.P. Morgan Securities LLC collect at 1-212-834-4533, Morgan Stanley & Co. LLC at 1-866-718-1649, Barclays Capital Inc. at 1-888-603-5847 and Mizuho Securities USA LLC at 1-866-271-7403.

     

    *The Issuer expects to deliver the Notes against payment for the Notes on or about February 26, 2025, which will be the sixth business day following the date of the pricing of the Notes (this settlement cycle being referred to as “T+6”). Under Rule 15c6-1 of the Exchange Act, trades in the secondary market generally are required to settle in one business day, unless the parties to a trade expressly agree otherwise. Accordingly, purchasers who wish to trade Notes on the date of pricing will be required, by virtue of the fact that the Notes initially will settle in T+6, to specify alternative settlement arrangements to prevent a failed settlement.

     

    **These Issuer ratings are not a recommendation to buy, sell or hold the Notes offered hereby. The ratings may be subject to revision or withdrawal at any time by the relevant rating agency. Each of the Issuer ratings included herein should be evaluated independently of any other Issuer rating.

     

    Terms used but not defined herein shall have the meanings ascribed thereto in the Issuer’s preliminary prospectus supplement, dated February 18, 2025, to the Issuer’s prospectus, dated February 14, 2025.

     

     3 

     

    Get the next $ABBV alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $ABBV

    DatePrice TargetRatingAnalyst
    4/22/2025$210.00Overweight
    Cantor Fitzgerald
    12/10/2024$191.00Neutral
    BofA Securities
    12/5/2024$180.00Outperform → Neutral
    Daiwa Securities
    11/22/2024$206.00Market Perform → Outperform
    Leerink Partners
    11/15/2024$205.00Outperform
    Wolfe Research
    11/4/2024Hold → Buy
    Argus
    10/17/2024$203.00Mkt Perform
    Bernstein
    6/5/2024$185.00Hold → Buy
    HSBC Securities
    More analyst ratings

    $ABBV
    Financials

    Live finance-specific insights

    See more
    • AbbVie Reports First-Quarter 2025 Financial Results

      Reports First-Quarter Diluted EPS of $0.72 on a GAAP Basis, a Decrease of 6.5 Percent; Adjusted Diluted EPS of $2.46, an Increase of 6.5 Percent; These Results Include an Unfavorable Impact of $0.13 Per Share Related to Acquired IPR&D and Milestones Expense  Delivers First-Quarter Net Revenues of $13.343 Billion, an Increase of 8.4 Percent on a Reported Basis or 9.8 Percent on an Operational Basis  First-Quarter Global Net Revenues from the Immunology Portfolio Were $6.264 Billion, an Increase of 16.6 Percent on a Reported Basis, or 18.1 Percent on an Operational Basis; Global Skyrizi Net Revenues Were $3.425 Billion; Global Rinvoq Net Revenues Were $1.718 Billion; Global Humira Net Revenues

      4/25/25 7:43:00 AM ET
      $ABBV
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • AbbVie to Host First-Quarter 2025 Earnings Conference Call

      NORTH CHICAGO, Ill., March 31, 2025 /PRNewswire/ -- AbbVie (NYSE:ABBV) will announce its first-quarter 2025 financial results on Friday, April 25, 2025, before the market opens. AbbVie will host a live webcast of the earnings conference call at 8 a.m. Central time. It will be accessible through AbbVie's Investor Relations website at investors.abbvie.com. An archived edition of the session will be available later that day. About AbbVie AbbVie's mission is to discover and deliver innovative medicines and solutions that solve serious health issues today and address the medical challenges of tomorrow. We strive to have a remarkable impact on people's lives across several key therapeutic areas in

      3/31/25 8:00:00 AM ET
      $ABBV
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • AbbVie and Gubra Announce License Agreement to Develop an Amylin Analog for the Treatment of Obesity

      Partnership marks AbbVie's entrance into the obesity fieldAgreement will enable the incorporation of GUB014295, an amylin peptide discovered and developed by Gubra, into AbbVie's global infrastructure for developing and commercializing therapies for patients in needNORTH CHICAGO, Ill. and HØRSHOLM, Denmark, March 3, 2025 /PRNewswire/ -- AbbVie (NYSE:ABBV) and Gubra A/S (CPSE:GUBRA), a company specializing in preclinical contract research services and peptide-based drug discovery within metabolic and fibrotic diseases, today announced a license agreement to develop GUB014295, a potential best-in-class, long-acting amylin analog for the treatment of obesity. "At AbbVie, we are focused on trans

      3/3/25 1:11:00 AM ET
      $ABBV
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ABBV
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Cantor Fitzgerald initiated coverage on AbbVie with a new price target

      Cantor Fitzgerald initiated coverage of AbbVie with a rating of Overweight and set a new price target of $210.00

      4/22/25 7:59:33 AM ET
      $ABBV
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • BofA Securities resumed coverage on AbbVie with a new price target

      BofA Securities resumed coverage of AbbVie with a rating of Neutral and set a new price target of $191.00

      12/10/24 8:12:28 AM ET
      $ABBV
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • AbbVie downgraded by Daiwa Securities with a new price target

      Daiwa Securities downgraded AbbVie from Outperform to Neutral and set a new price target of $180.00

      12/5/24 7:33:20 AM ET
      $ABBV
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ABBV
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    See more
    • FDA Approval for VYALEV issued to ABBVIE INC

      Submission status for ABBVIE INC's drug VYALEV (ORIG-1) with active ingredient FOSCARBIDOPA AND FOSLEVODOPA has changed to 'Approval' on 10/16/2024. Application Category: NDA, Application Number: 216962, Application Classification: Type 3 - New Dosage Form and Type 4 - New Combination

      10/18/24 4:38:13 AM ET
      $ABBV
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • FDA Approval for VYALEV issued to ABBVIE INC

      Submission status for ABBVIE INC's drug VYALEV (ORIG-1) with active ingredient FOSCARBIDOPA AND FOSLEVODOPA has changed to 'Approval' on 10/16/2024. Application Category: NDA, Application Number: 216962, Application Classification: Type 3 - New Dosage Form

      10/17/24 1:29:31 PM ET
      $ABBV
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • FDA Approval for SKYRIZI issued to ABBVIE INC

      Submission status for ABBVIE INC's drug SKYRIZI (SUPPL-7) with active ingredient RISANKIZUMAB-RZAA has changed to 'Approval' on 06/18/2024. Application Category: BLA, Application Number: 761262, Application Classification:

      6/21/24 4:38:17 AM ET
      $ABBV
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ABBV
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Gonzalez Richard A gifted 2,450 shares, decreasing direct ownership by 0.63% to 386,479 units (SEC Form 4)

      4 - AbbVie Inc. (0001551152) (Issuer)

      4/2/25 5:00:15 PM ET
      $ABBV
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Director Alpern Robert J

      4 - AbbVie Inc. (0001551152) (Issuer)

      4/2/25 5:00:16 PM ET
      $ABBV
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Director Quaggin Susan E

      4 - AbbVie Inc. (0001551152) (Issuer)

      4/2/25 5:00:10 PM ET
      $ABBV
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ABBV
    Leadership Updates

    Live Leadership Updates

    See more
    • AbbVie Appoints CEO Robert A. Michael as Chairman of the Board of Directors

      Richard A. Gonzalez to retire from the board of directors effective July 1, 2025NORTH CHICAGO, Ill., Feb. 14, 2025 /PRNewswire/ -- AbbVie (NYSE:ABBV) today announced that its board of directors has unanimously elected chief executive officer (CEO) Robert A. Michael to assume the additional position of chairman, effective July 1, 2025. He will succeed Richard A. Gonzalez, who formerly served as AbbVie's CEO and has been chairman since the Company's formation in 2013. "I want to extend my heartfelt gratitude to Rick for his remarkable leadership and dedicated service," said Roxanne S. Austin, lead independent director. "The board and I have complete confidence in Rob, and we are fortunate to

      2/14/25 7:40:00 AM ET
      $ABBV
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • PureTech Founded Entity Seaport Therapeutics Names Lauren White as Chief Financial Officer

      Former ImmunoGen CFO will join Seaport to steer capital financing strategy, accounting, FP&A and investor relations PureTech Health plc (NASDAQ:PRTC, LSE: PRTC)) ("PureTech" or the "Company"), a clinical-stage biotherapeutics company, noted that its Founded Entity, Seaport Therapeutics, ("Seaport") a biopharmaceutical company that is advancing novel neuropsychiatric medicines with a proven strategy and team, today announced the appointment of Lauren White as Chief Financial Officer. An accomplished biotech financial executive, Ms. White most recently served as the Chief Financial Officer at ImmunoGen (NASDAQ:IMGN) prior to its acquisition by AbbVie (NYSE:ABBV) for $10.1 billion in 2024. T

      11/5/24 7:05:00 AM ET
      $ABBV
      $CCCC
      $IMGN
      $NVS
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Biotechnology: Biological Products (No Diagnostic Substances)
    • Seaport Therapeutics Names Lauren White as Chief Financial Officer

      Former ImmunoGen CFO will join Seaport to steer capital financing strategy, accounting, FP&A and investor relations Seaport Therapeutics ("Seaport or the "Company"), a clinical-stage biopharmaceutical company that is advancing novel neuropsychiatric medicines with a proven strategy and team, today announced the appointment of Lauren White as Chief Financial Officer. An accomplished biotech financial executive, Ms. White most recently served as the Chief Financial Officer at ImmunoGen (NASDAQ:IMGN) prior to its acquisition by AbbVie (NYSE:ABBV) for $10.1 billion in 2024. "I am so pleased to welcome Lauren as our CFO as we progress our clinical-stage pipeline of therapeutics for the treatme

      11/5/24 7:00:00 AM ET
      $ABBV
      $CCCC
      $IMGN
      $NVS
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Biotechnology: Biological Products (No Diagnostic Substances)

    $ABBV
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • AbbVie to Present at the Bank of America Securities Healthcare Conference

      NORTH CHICAGO, Ill., May 6, 2025 /PRNewswire/ -- AbbVie (NYSE:ABBV) will participate in the Bank of America Securities Healthcare Conference on Wednesday, May 14, 2025. Management will participate in a fireside chat at 12:00 p.m. Central time. A live audio webcast of the presentation will be accessible through AbbVie's Investor Relations website at investors.abbvie.com. An archived edition of the session will be available later that day. About AbbVie AbbVie's mission is to discover and deliver innovative medicines and solutions that solve serious health issues today and address the medical challenges of tomorrow. We strive to have a remarkable impact on people's lives across several key ther

      5/6/25 8:00:00 AM ET
      $ABBV
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • BOTOX® Cosmetic (onabotulinumtoxinA) Continues its Mission of Empowering Entrepreneurs Through "The Confidence Project"

      BOTOX® Cosmetic Will Provide 250 Entrepreneurs with Access to New Resources and Opportunities and Will Award 20 Grants Worth $20,000 Each to Support Business Goals.By 2030, BOTOX® Cosmetic Pledges to Empower 50,000 Entrepreneurs, Helping to Close the Confidence Gap.IRVINE, Calif., May 1, 2025 /PRNewswire/ -- Allergan Aesthetics, an AbbVie company (NYSE:ABBV), today announced BOTOX® Cosmetic's continued commitment to closing the Confidence Gap with the introduction of The Confidence Project: Empowering Women Entrepreneurs. The one & only BOTOX® Cosmetic invites business owners to apply for this year's program starting today through May 9, 2025, at 11:59pm PT.

      5/1/25 5:00:00 PM ET
      $ABBV
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • RINVOQ® (upadacitinib) Receives U.S. FDA Approval for Giant Cell Arteritis (GCA)

      –      RINVOQ (upadacitinib) is now the first and only oral Janus Kinase (JAK) inhibitor approved for the treatment of GCA in adults–      Also known as temporal arteritis, GCA is the most common vasculitis affecting adults in Western countries2 –      This marks the ninth approved indication for RINVOQ in the U.S., across rheumatology, gastroenterology, and dermatology1 NORTH CHICAGO, Ill., April 29, 2025 /PRNewswire/ -- AbbVie (NYSE:ABBV) today announced the U.S. Food and Drug Administration (FDA) has approved RINVOQ® (upadacitinib), 15 mg, once daily, for the treatment of adults with giant cell arteritis (GCA).1 This comes after the European Commission recently granted marketing authoriza

      4/29/25 7:30:00 AM ET
      $ABBV
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ABBV
    SEC Filings

    See more
    • AbbVie Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - AbbVie Inc. (0001551152) (Filer)

      4/25/25 7:48:22 AM ET
      $ABBV
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • AbbVie Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - AbbVie Inc. (0001551152) (Filer)

      4/3/25 4:13:07 PM ET
      $ABBV
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 144 filed by AbbVie Inc.

      144 - AbbVie Inc. (0001551152) (Subject)

      3/31/25 5:30:00 PM ET
      $ABBV
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ABBV
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by AbbVie Inc. (Amendment)

      SC 13G/A - AbbVie Inc. (0001551152) (Subject)

      2/13/24 4:55:55 PM ET
      $ABBV
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by AbbVie Inc. (Amendment)

      SC 13G/A - AbbVie Inc. (0001551152) (Subject)

      1/25/24 4:59:27 PM ET
      $ABBV
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by AbbVie Inc. (Amendment)

      SC 13G/A - AbbVie Inc. (0001551152) (Subject)

      2/9/23 10:54:46 AM ET
      $ABBV
      Biotechnology: Pharmaceutical Preparations
      Health Care